Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
XORTX Therapeutics Inc ( (TSE:XRTX) ) just unveiled an announcement.
XORTX Therapeutics Inc. plans to nominate three new directors, George Scorsis, Richard Grieve, and Mika Grasso, at its March 24, 2026 annual and special shareholder meeting, replacing three previously proposed nominees. The board changes are a condition of a significant financing initiative currently under negotiation, which, if not completed, will see the new directors resign and their seats refilled later, with the financing also requiring TSX Venture Exchange approval.
The proposed directors bring experience in highly regulated industries, finance, operations, and investment management, notably including Scorsis’s track record scaling consumer and cannabis businesses and executing major M&A and financing transactions. Their addition is intended to support XORTX’s capital-raising efforts and may strengthen governance and strategic execution as the company advances its late-stage pharmaceutical programs.
The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.48 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on XRTX Stock
According to Spark, TipRanks’ AI Analyst, XRTX is a Neutral.
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn despite some improvement) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company developing innovative therapies to treat gout and progressive kidney disease. Listed on Nasdaq, the TSX Venture Exchange, and Frankfurt, the company focuses on addressing unmet needs in renal and metabolic disorders through advanced drug development programs.
Average Trading Volume: 7,666
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$3.55M
Learn more about XRTX stock on TipRanks’ Stock Analysis page.